Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003603:Cytotoxins / Q000627:therapeutic use; D000077143:Docetaxel; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005971:Glutamates / Q000627:therapeutic use; D005978:Glutathione / Q000031:analogs & derivatives / Q000627:therapeutic use; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068437:Pemetrexed; D011355:Prodrugs; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use
D003603:Cytotoxins; D005971:Glutamates; D011355:Prodrugs; D011799:Quinazolines; D043823:Taxoids; D000068437:Pemetrexed; C107479:TER 286; D000077143:Docetaxel; D006147:Guanine; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D005978:Glutathione; D017239:Paclitaxel